Preeclampsia - Two manifestations of the same disease;Stan przedrzucawkowy - Dwie postacie tej samej choroby

Ginekologia Polska

Volumn 79, Issue 6, 2008, Pages 432-437

  Kornacki, Jakub ^a   Skrzypczak, Jana ^a  

^a Klinika Rozrodczo ci   (Poland)

Author keywords

Metabolic syndrome placenta; Preeclampsia

Indexed keywords

DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MATERNAL HYPERTENSION; METHODOLOGY; NEWBORN; OBESITY; PARITY; PATHOPHYSIOLOGY; PREECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PRENATAL CARE; PROGNOSIS; REVIEW; RISK FACTOR;

DIABETES MELLITUS; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERTENSION; HYPERTENSION, PREGNANCY-INDUCED; INFANT, NEWBORN; INSULIN RESISTANCE; OBESITY; PARITY; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PRENATAL CARE; PROGNOSIS; RISK FACTORS;

EID: 48849084763     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Roberts J, Pearson G, Cutler J, [et al.]. Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy. Hypertension. 2003, 41, 437-445.
2. Kornacki J, Koźlik J, Dubiel M, [et al.] Ocena stresu oksydacyjnego i jego korelacji z przepływami krwi w tetnicach macicznych u kobiet ze stanem przedrzucawkowym. Ginekol Pol. 2004, 75, 681-691.
3. Kornacki J, Skrzypczak J. Rola hiperlipidemii oraz stresu oksydacyjnego w etiopatogenezie nadciśnienia indukowanego ciaża. Ginekol Pol. 2003, 74, 168-176.
4. Zhang P, Schmidt M, Cook L. Maternal vasculopathy and histologic diagnosis of preeclampsia: poor correlation of histologic changes and clinical manifestation. Am J Obstet Gynecol. 2006, 194, 1050-1056.
5. Pi-Sunyer X. The Metabolic Syndrome: How to Approach Differing Definitions. Med Clin North Am. 2007, 91, 1025-1040.
6. Samules-Kalow M, Funai E, Buhimschi C, [et al.]. Prepregnancy body mass index, hypertensive disorders of pregnancy, and long-term maternal mortality. Am J Obstet Gynecol. 2007, 197, 490.e1-490.e6.
7. Walsh S. Obesity: a risk factor for preeclampsia. Trends Endocrinol Metab. 2007, 18, 365-370.
8. August P, Helseth G, Cook E, [et al.]. A prediction model for superimposed preeclampsia in women with chronic hypertension during pregnancy. Am J Obstet Gynecol. 2004, 191, 1666-1672.
9. Solomon C, Graves S, Greene M, [et al.]. Glucose intolerance as a predictor of hypertension in pregnancy. Hypertension. 1994, 23, 717-721.
10. Sermer M, Naylor C, Gare D, [et al.]. Impact of increasing carbohydrate intolerance on maternal-fetal outcomes in 3637 women without gestational diabetes The Toronto Tri-Hopsital Gestational Diabetes Project. Am J Obstet Gynecol. 1995, 173, 146-156.
11. Thadhani R, Ecker J, Mutter W, [et al.]. Insulin resistance and alterations in angiogenesis: additive insults that may lead to preeclampsia. Hypertension. 2004, 43, 988-992.
12. Paretti E, Lapolla A, Dalfra M, [et al.]. Preeclampsia in lean normotensive normotolerant pregnant women can be predicted by simple insulin sensitivity indexes. Hypertension. 2006, 47, 449-453.
13. Wolf M, Sandler L, Jimenez-Kimble R. [et al.]. Insulin Resistance But Not Inflammation Is Associated With Gestational Hypertension. Hypertension. 2002, 40, 886-891.
14. Solomon C, Seely E. Brief Review: Hypertension in Pregnancy: A Manifestation of the Insulin Resistance Syndrome? Hypertension. 2001, 37, 232-239.
15. Matthews D, Hosker J, Rudenski A, [et al.]. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985, 28, 412-419.
16. Katz A, Nambi S, Mather K, [et al.]. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000, 85, 2402-2410.
17. Wolf M, Sandler L, Munoz K, [et al.]. First Trimester Insulin Resistance and Subsequent Preeclampsia: A Prospective Study. J Clin Endocrinol Metab. 2002, 87, 1563-1568.
18. Gjonnaess H. The course and outcome of pregnancy after ovarian electrocautery in women with polycystic ovarian syndrome: the influence of body-weight. Br J Obstet Gynecol. 1989, 96, 714-719.
19. Fridstrom M, Nisell H, Sjoblom P, [et al.]. Are women with polycystic ovary syndrome at an increased risk of pregnancy-induced hypertension and/or preeclampsia? Hypertens Pregnancy. 1999, 18, 73-80.
20. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ. 2005, 330, 565.
21. Nordlander E, Hanson U, Persson B. Factors influencing neonatal morbidity in gestational diabetic pregnancy. Br J Obstet Gynecol. 1989, 96, 671-678.
22. Berkowitz G, Roman S, Lapinsky R, [et al.]. Maternal characteristics, neonatal outcome, and the time of diagnosis of gestational diabetes. Am J Obstet Gynecol. 1992, 167, 976-982.
23. Dunne F, Brydon P, Smith K, [et al.]. Pregnancy in women with type 2 diabetes: 12 years outcome data 1990-2002. Diabet. Med. 2003, 20, 734-738.
24. Howarth H, Gazis A, James D. Association of Type 1 diabetes mellitus, maternal vascular disease and complications of pregnancy. Diabet Med. 2007, 24, 1229-1234.
25. Catov J, Ness R, Kip K, [et al.]. Risk of early or severe preeclampsia related to preexisting conditions. Int J Epidemiol. 2007, 36, 412-419.
26. Bodnar L, Ness R, Markovic N, [et al.]. The risk of preeclampsia rises with increasing prepregnancy body mass index. Ann Epidemiol. 2005, 15, 475-482.
27. Villamor E, Cnattingius S. Interpregnancy weight change and risk of adverse pregnancy outcomes: a population-based study. Lancet. 2006, 368, 1164-1170.
28. Kornacki J, Koźlik J, Skrzypczak J. Lipid profile and oxidative stress in women with mild and severe preeclampsia. Arch Perinat Med. 2003, 9, 40-44.
29. Clausen T, Djurovic S, Henriksen T. Dyslipidemia in early second trimester is mainly a feature of women with early-onset preeclampsia. BJOG. 2001, 108, 1081-1087.
30. Enquobahrie D, Williams M, Butler C, [et al.]. Maternal plasma lipid concentrations in early pregnancy and risk of preeclampsia. Am J Hypertens. 2004, 17, 574-581.
31. Redman C, Sargent I. Latest Advances in Understanding Preeclampsia. Science. 2005, 308, 1592-1594.
32. Levine R, Lam C, Qian C, [et al.]. Soluble Endoglin and Other Circulating Antiangiogenic Factors in Preeclampsia. N Eng J Med. 2006, 355, 992-1005.
33. Luft F. Soluble endoglin (sEng) joins the soluble fms-like tyrosine kinase (sFlt) receptor as a pre-eclampsia molecule. Nephrol Dial Transplant. 2006, 21, 3052-3054.
34. Thadhani R, Mutter W, Wolf M, [et al.]. First trimester Growth Factor and Soluble Fms-Like Tyrosine Kinase 1 and Risk for Preeclampsia. J Clin Endocrinol Metab. 2004, 89, 770-775.
35. Dubiel M. Ultrasonografia dopplerowska w ocenie układu krażenia płodu w ciaży powikłanej nadciśnieniem tetniczym indukowanym ciaża. W: Kliniczna Perinatologia i Ginekologia. Red. Słomko Z, Breborowicz GH, Gadzinowski J. Poznań: OWN. 2000.
36. Gramellini D, Folli M, Raboni S, [et al.]. Cerebral -umbilical Doppler ratio as a predictor of adverse perinatal outcome. Obstet Gynecol. 1992, 79, 416-420.
37. Bilardo C, Wolf H, Stigter R, [et al.]. Relationship between monitoring parameters and perinatal outcome in severe, early intrauterine growth restriction. Ultrasound Obstet Gynecol. 2004, 23, 119-125.
38. Baschat A, Gembruch U, Weiner C, [et al.}. Qualitative venous Doppler waveform analysis improves prediction of critical perinatal outcomes in premature growth-restricted fetuses. Ultrasound Obstet Gynecol. 2003, 22, 240-245.
39. Mari G, Hanif F. Intrauterine Growth Restriction: How to Manage and When to Deliver. Clin Obstet Gynecol. 2007, 50, 497-509.